| abstract |
The present invention relates to Factor VII (FVII), wherein the variant comprises amino acid substitutions at positions 10 and 32, and the variant further comprises a sugar moiety covalently linked to an introduced in vivo N-glycosylation site present outside the Gla domain. It relates to novel polypeptide variants of factor or factor VIIa (FVIIa) polypeptides. Such polypeptide variants are useful in therapy, particularly to treat a variety of coagulation related disorders such as trauma. |